Recombinant Anti-CCL4/MIP-1 beta antibody [EPR23610-40] (ab254371)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR23610-40] to CCL4/MIP-1 beta
- Suitable for: ICC, Flow Cyt, Dot blot
- Reacts with: Mouse, Human
Overview
-
Product name
Anti-CCL4/MIP-1 beta antibody [EPR23610-40]
See all CCL4/MIP-1 beta primary antibodies -
Description
Rabbit monoclonal [EPR23610-40] to CCL4/MIP-1 beta -
Host species
Rabbit -
Specificity
This antibody has cross-reactivity with CCL4L1. There is about 97% homology between CCL4/MIP-1 beta and CCL4L1 in terms of the immunogen designed from CCL4/MIP-1 beta.
-
Tested applications
Suitable for: ICC, Flow Cyt, Dot blotmore details
Unsuitable for: IHC-P,IP or WB -
Species reactivity
Reacts with: Mouse, Human -
Immunogen
Recombinant fragment within Human CCL4/MIP-1 beta aa 1 to the C-terminus. The exact sequence is proprietary.
Database link: P13236 -
Positive control
- ICC: THP-1 cells (treated with PMA, 100nM for 16 hours, then with lipopolysaccharide (LPS, 100 ng/ml) for 4 hours and with BFA (1 µg/ml) for another 3 hours.). Flow cyt: THP-1 (treated with 100nM phorbol 12-myristate 13-acetate (PMA) for 16 hours, then 100 ng/ml lipopolysaccharide (LPS) for 4 hours and add 1 ug/ml Brefeldin A (BFA) for another 3 hours) and RAW 264.7 cells (treated with 100 ng/ml lipopolysaccharide (LPS) for 4 hours and 1 ug/ml Brefeldin A (BFA) for another 3 hours).
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.01% Sodium azide
Constituents: 59.94% PBS, 40% Glycerol, 0.05% BSA -
Concentration information loading... -
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR23610-40 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
Applications
Our Abpromise guarantee covers the use of ab254371 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| ICC | 1/100. | |
| Flow Cyt | 1/50. | |
| Dot blot | 1/1000. |
Target
-
Function
Monokine with inflammatory and chemokinetic properties. Binds to CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-beta induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form MIP-1-beta(3-69) retains the abilities to induce down-modulation of surface expression of the chemokine receptor CCR5 and to inhibit the CCR5-mediated entry of HIV-1 in T-cells. MIP-1-beta(3-69) is also a ligand for CCR1 and CCR2 isoform B. -
Sequence similarities
Belongs to the intercrine beta (chemokine CC) family. -
Post-translational
modificationsN-terminal processed form MIP-1-beta(3-69) is produced by proteolytic cleavage after secretion from peripheral blood lymphocytes. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 388372 Human
- Entrez Gene: 6351 Human
- Entrez Gene: 9560 Human
- Entrez Gene: 20303 Mouse
- Omim: 182284 Human
- Omim: 603782 Human
- Omim: 610757 Human
- SwissProt: P13236 Human
see all -
Alternative names
- MIP 1 beta antibody
- Secreted protein G 26 antibody
- ACT 2 antibody
see all
Images
-
![Flow Cytometry - Anti-CCL4/MIP-1 beta antibody [EPR23610 -40] (ab254371)](https://www.abcam.com/ps/products/254/ab254371/Images/ab254371-2-anti-ccl4mip1-beta-antibody-epr2361040-flow-cytometry-thp1.jpg)
Flow Cytometry - Anti-CCL4/MIP-1 beta antibody [EPR23610 -40] (ab254371)Flow cytometric analysis of 4% paraformaldehyde fixed 90% methanol permeabilized THP-1 (Human monocytic leukemia monocyte) (treated with 100nM phorbol 12-myristate 13-acetate (PMA) for 16 hours, then 100 ng/ml lipopolysaccharide (LPS) for 4 hours and add 1 ug/ml Brefeldin A (BFA) for another 3 hours) (Red)/Untreated control (Green) cells labelling CCL4/MIP-1 beta with ab254371 at 1/500 dilution (0.1ug)/ compared with a Rabbit monoclonal IgG (ab172730) isotype control (Black) and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (Blue).
A Goat anti-rabbit IgG (Alexa Fluor® 488, ab150077) at 1/2000 dilution was used as the secondary antibody.
The expression pattern is consistent with what is described in the literature (PMID:29669317).
-
![Immunocytochemistry - Anti-CCL4/MIP-1 beta antibody [EPR23610 -40] (ab254371)](https://www.abcam.com/ps/products/254/ab254371/Images/ab254371-1-anti-ccl4mip1-beta-antibody-epr2361040-immunocytochemistry-thp1.jpg)
Immunocytochemistry - Anti-CCL4/MIP-1 beta antibody [EPR23610 -40] (ab254371)Immunofluorescent analysis of 4% Paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized THP-1 cells labelling CCL4/MIP-1 beta with ab254371 at 1/100 (5.45 ug/ml) dilution, followed by ab150077 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) antibody at 1/1000 dilution (Green). Confocal image showing cytoplasmic staining in THP-1 cells treated with phorbol 12-myristate 13-acetate (PMA, 100nM) for 16 hours, then with lipopolysaccharide (LPS, 100 ng/ml) for 4 hours and with BFA (1 ug/ml) for another 3 hours. ab195889 Anti-alpha Tubulin mouse monoclonal antibody - Microtubule Marker (Alexa Fluor® 594) was used to counterstain tubulin at 1/200 (Red). The Nuclear counterstain was DAPI (Blue).
Secondary antibody only control: Secondary antibody is ab150077 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) at 1/1000 dilution.
-
![Dot Blot - Anti-CCL4/MIP-1 beta antibody [EPR23610 -40] (ab254371)](https://www.abcam.com/ps/products/254/ab254371/Images/ab254371-4-anti-ccl4mip1-beta-antibody-epr2361040-dotblot-human-ccl4mip1-beta-immunogen-recombinant-protein.jpg)
Dot Blot - Anti-CCL4/MIP-1 beta antibody [EPR23610 -40] (ab254371)Dot blot analysis of CCL4/MIP-1 beta using ab254371 at 1/1000 (0.545ug/ml) dilution followed by a Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/20,000 dilution.
Lane 1: Human CCL4/MIP-1 beta immunogen recombinant protein
Lane 2: Human CCL4L1 recombinant protein
Lane 3: Bovine serum albumin (BSA)
Blocking and diluting buffer and concentration: 5% NFDM/TBST.
Exposure time: 114 seconds
-
![Flow Cytometry - Anti-CCL4/MIP-1 beta antibody [EPR23610 -40] (ab254371)](https://www.abcam.com/ps/products/254/ab254371/Images/ab254371-3-anti-ccl4mip1-beta-antibody-epr2361040-flow-cytometry-raw-2647.jpg)
Flow Cytometry - Anti-CCL4/MIP-1 beta antibody [EPR23610 -40] (ab254371)Flow cytometric analysis of 4% paraformaldehyde-fixed, 90% methanol-permeabilized RAW 264.7 (mouse Abelson murine leukemia virus-induced tumor macrophage) (treated with 100 ng/ml lipopolysaccharide (LPS) for 4 hours and 1 ug/ml Brefeldin A (BFA) for another 3 hours) (Red) /Untreated control (Green) cells labelling CCL4/MIP-1 beta with ab254371 at 1/50 dilution (1ug)/ compared with a Rabbit monoclonal IgG (ab172730) isotype control (Black) and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (Blue).
A Goat anti-rabbit IgG (Alexa Fluor® 488, ab150077) at 1/2000 dilution was used as the secondary antibody.
The expression pattern is consistent with what is described in the literature (PMID:32230927).
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
Certificate of Compliance
References (0)
ab254371 has not yet been referenced specifically in any publications.
